These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

307 related items for PubMed ID: 8976102

  • 1. [How to select and use urate lowering agents for hyperuricemia].
    Yamanaka H.
    Nihon Rinsho; 1996 Dec; 54(12):3261-5. PubMed ID: 8976102
    [Abstract] [Full Text] [Related]

  • 2. [Uricosuric agent].
    Ohno I.
    Nihon Rinsho; 2008 Apr; 66(4):743-7. PubMed ID: 18409525
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
    Akkasilpa S, Osiri M, Deesomchok U, Avihingsanon Y.
    J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
    [Abstract] [Full Text] [Related]

  • 4. [Establishment of therapeutic goal and plan of gout and asymptomatic hyperuricemia].
    Fujimori S.
    Nihon Rinsho; 2008 Apr; 66(4):729-35. PubMed ID: 18409523
    [Abstract] [Full Text] [Related]

  • 5. Recent approaches to gout drug discovery: an update.
    Otani N, Ouchi M, Kudo H, Tsuruoka S, Hisatome I, Anzai N.
    Expert Opin Drug Discov; 2020 Aug; 15(8):943-954. PubMed ID: 32329387
    [Abstract] [Full Text] [Related]

  • 6. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level.
    Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT.
    Clin Pharmacol Ther; 2011 Sep; 90(3):392-8. PubMed ID: 21796116
    [Abstract] [Full Text] [Related]

  • 7. A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout.
    Reinders MK, Haagsma C, Jansen TL, van Roon EN, Delsing J, van de Laar MA, Brouwers JR.
    Ann Rheum Dis; 2009 Jun; 68(6):892-7. PubMed ID: 18633127
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Risk factors associated with renal lithiasis during uricosuric treatment of hyperuricemia in patients with gout.
    Perez-Ruiz F, Hernandez-Baldizon S, Herrero-Beites AM, Gonzalez-Gay MA.
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1299-305. PubMed ID: 20506124
    [Abstract] [Full Text] [Related]

  • 12. On call. I've had gout for many years. I used to take Zyloprim without any problems, but I just had a severe allergic reaction, so my doctor switched me to Benemid. I'm doing okay, but the drug sometimes upsets my stomach. Do you have any suggestions?
    Simon HB.
    Harv Mens Health Watch; 2010 Jan; 14(6):7-8. PubMed ID: 20464796
    [No Abstract] [Full Text] [Related]

  • 13. Improvement of renal function in patients with chronic gout after proper control of hyperuricemia and gouty bouts.
    Perez-Ruiz F, Calabozo M, Herrero-Beites AM, García-Erauskin G, Pijoan JI.
    Nephron; 2000 Nov; 86(3):287-91. PubMed ID: 11096285
    [Abstract] [Full Text] [Related]

  • 14. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial.
    Schumacher HR, Becker MA, Wortmann RL, Macdonald PA, Hunt B, Streit J, Lademacher C, Joseph-Ridge N.
    Arthritis Rheum; 2008 Nov 15; 59(11):1540-8. PubMed ID: 18975369
    [Abstract] [Full Text] [Related]

  • 15. [Hyperuricemia and gout--treatment].
    Gröbner W, Walter-Sack I.
    Dtsch Med Wochenschr; 2002 Feb 01; 127(5):210-3. PubMed ID: 11821994
    [No Abstract] [Full Text] [Related]

  • 16. Safety of urate-lowering therapies: managing the risks to gain the benefits.
    Keenan RT.
    Rheum Dis Clin North Am; 2012 Nov 01; 38(4):663-80. PubMed ID: 23137576
    [Abstract] [Full Text] [Related]

  • 17. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output.
    Perez-Ruiz F, Calabozo M, Erauskin GG, Ruibal A, Herrero-Beites AM.
    Arthritis Rheum; 2002 Dec 15; 47(6):610-3. PubMed ID: 12522834
    [Abstract] [Full Text] [Related]

  • 18. Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials.
    Wortmann RL, Macdonald PA, Hunt B, Jackson RL.
    Clin Ther; 2010 Dec 15; 32(14):2386-97. PubMed ID: 21353107
    [Abstract] [Full Text] [Related]

  • 19. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
    Hanvivadhanakul P, Akkasilpa S, Deesomchok U.
    J Med Assoc Thai; 2002 Jun 15; 85 Suppl 1():S40-7. PubMed ID: 12188443
    [Abstract] [Full Text] [Related]

  • 20. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
    Halpern R, Mody RR, Fuldeore MJ, Patel PA, Mikuls TR.
    Curr Med Res Opin; 2009 Jul 15; 25(7):1711-9. PubMed ID: 19485724
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.